Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic.
Antiviral Agents
Betacoronavirus
COVID-19
Coronavirus Infections
/ complications
Europe
Humans
Immunosuppressive Agents
/ therapeutic use
Kidney Diseases
/ complications
Nephrology
/ standards
Pandemics
Pneumonia, Viral
/ complications
Renal Dialysis
Retrospective Studies
Risk Assessment
Risk Factors
SARS-CoV-2
Societies, Medical
COVID-19
glomerulonephritis
lupus
renal vasculitis
steroids
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
received:
14
04
2020
accepted:
19
04
2020
pubmed:
24
5
2020
medline:
1
7
2020
entrez:
24
5
2020
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic has created major challenges for all countries around the globe. Retrospective studies have identified hypertension, cardiovascular disease, diabetes and older age as risk factors for high morbidity and mortality from COVID-19. There is a general concern that patients with immune-mediated kidney diseases, namely those on immunosuppressive therapies and/or those with more advanced kidney failure, could particularly be at risk for adverse outcomes due to a compromised antiviral immunity. Uncertainties exist on how management routines should be reorganized to minimize the risk of severe acute respiratory syndrome coronavirus 2 infection and what measures are necessary for infected patients. The aim of the present review of the Immunonephrology Working Group of the European Renal Association-European Dialysis and Transplant Association is to provide recommendations for the management of patients with immune-mediated kidney diseases based on the available evidence, similar circumstances with other infectious organisms and expert opinions from across Europe. Such recommendations may help to minimize the risk of encountering COVID-19 or developing complications during COVID-19 in patients with immune-mediated kidney disease.
Identifiants
pubmed: 32445573
pii: 5843427
doi: 10.1093/ndt/gfaa112
pmc: PMC7313759
doi:
Substances chimiques
Antiviral Agents
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Practice Guideline
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
920-925Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Rheumatol. 2018 Aug;37(8):2081-2086
pubmed: 29667100
J Autoimmun. 2020 May;109:102442
pubmed: 32253068
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):525
pubmed: 32220656
J Nephrol. 2020 Apr;33(2):193-196
pubmed: 32207068
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
Eur J Radiol. 2020 May;126:108961
pubmed: 32229322
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Kidney Int Rep. 2020 Apr 04;5(5):580-585
pubmed: 32292866
PLoS Pathog. 2011 Oct;7(10):e1002331
pubmed: 22046132
Lancet. 2020 Mar 14;395(10227):912-920
pubmed: 32112714
Autoimmun Rev. 2018 Jul;17(7):653-659
pubmed: 29730524
Eur J Rheumatol. 2020 Aug;7(Suppl 2):S117-S120
pubmed: 32352359
Virus Res. 2014 May 12;184:44-53
pubmed: 24566223
Kidney Int. 2013 Jun;83(6):1010-6
pubmed: 23325079
Kidney Int. 2020 May;97(5):829-838
pubmed: 32247631
Kidney Int. 2020 May;97(5):824-828
pubmed: 32204907
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
Adv Chronic Kidney Dis. 2019 Jan;26(1):8-15
pubmed: 30876622
JAMA Cardiol. 2020 Jul 1;5(7):831-840
pubmed: 32219363
Nephrol Dial Transplant. 2020 May 1;35(5):737-741
pubmed: 32196116
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342
pubmed: 32202240